Chinese health media reporter Sharon walked into Qilu Pharmaceutical Group to talk about pharmaceutical and health industry innovation...

December 23, under the guidance of the China Pharmaceutical Enterprise Management Association, E drug manager, China Health Media Journalist Salon Working Committee, Qilu Pharmaceutical Group Co., Ltd. hosted by China Health Media Journalist Sharon "Innovation 100" enterprise visit action into Qilu Pharmaceutical Group.
From Beijing, Shanghai, Guangzhou, Hangzhou, Jinan and other places more than 20 authoritative chinese health media, visited Qilu Pharmaceutical's new exhibition hall, production and research and development base, and Qilu Pharmaceutical Group leaders on the industry hot spots, focus on exchanges and talks.
China Pharmaceutical Enterprise Management Association Vice President Tan Yong, Qilu Pharmaceutical Group Vice President Bao Haizhong, Zhang Han chang, Qilu Innovation Pharmaceutical Research Institute Executive Vice President Zhu Yidong, Qilu Pharmaceutical Group President's Office Deputy Director and Qilu Pharmaceutical Sales Corporation Deputy General Manager Sun Ying-man and other leaders attended the symposium.
meeting was chaired by Wu Gang, Deputy General Manager of Qilu Pharmaceutical Sales Corporation.
culture: focus on the people's health party central committee, the State Council attaches great importance to the development of health and health.
The Fifth Plenary Session of the 19th Central Committee of the Communist Party of China adopted the 14th Five-Year Plan and the 2035 Vision, comprehensively promoted the construction of a healthy China, accelerated China's leap from a pharmaceutical power to a pharmaceutical power, and effectively enhanced the people's sense of access, happiness and security.
struggle for the rise of a "healthy China", and the medical people are duty-bound.
Zhang Han, vice president of Qilu Pharmaceutical Group, said in his speech that as a leading enterprise in China's pharmaceutical innovation and internationalization, Qilu Pharmaceutical Group does not forget its original intentions and create a future, and actively participates in the "Healthy China" construction process, and continues to care for public health and safeguard human well-being.
Qilu Pharmaceutical Group Vice President Bao Haizhong said at the meeting, Qilu Pharmaceutical has always been with the country "same frequency resonance", firm support, full participation in the national drug belt procurement, there are currently 17 products winning the bid, 6 products fell by more than 90%, long-term commitment to do people to use, affordable domestic high-quality good medicine.
Ziru Pharmaceuticals has a saying that when we are sick, we are willing to choose Qilu Pharmaceuticals, when our families are sick, we can safely choose Qilu Pharmaceuticals, and when our friends are sick, we can proudly recommend Qilu Pharmaceuticals.
This sentence embodies two meanings, one is Qilu people always keep in mind the "patients as relatives, the whole process to protect the quality of drugs" concept, high quality of work to ensure product quality;
Innovation: Innovation towards the highest end of the pharmaceutical industry value chain is the soul of national progress, an insincestable source of national prosperity, and the most distinctive national endowment of the Chinese nation.
present, China's pharmaceutical industry with scientific and technological innovation enabling industry development, forming an independent innovation system to support the high-quality development of the industry, scientific and technological strength continues to strengthen, scientific research results have attracted worldwide attention.
Yong, vice president of the China Pharmaceutical Enterprise Management Association, said in a speech that the number of clinical studies and the number of new drugs on the market are important evaluation indicators of China's pharmaceutical innovation.
In the process of moving towards the first echelon of global pharmaceutical innovation, China's pharmaceutical innovation should do three things: first, to be clinical value-oriented, less follow the trend of piles;
of innovative pharmaceuticals, generics and biosimilars, innovative dosage forms and me better innovative drugs, the first innovative drugs to be developed independently and introduced/co-operated externally is the "troika" that builds competitiveness in drug research and development.
Zhu Yidong, executive vice president of Qilu Institute of Innovative Drugs, shared Qilu Pharmaceutical's innovative research and development progress in sharing "Research and development practices towards the highest end of the pharmaceutical industry value chain", keeping up with the development trend of international innovative drugs, and developing a global product line with core technologies such as small molecular pharmacological precision design platform, antibody combination, somavirus, nano-drug delivery, etc.
currently, more than 50 innovative drug research projects, a number of approved into clinical trials, this year there are 11 in China, the United States declared IND.
It is worth mentioning that PD1/CTLA-4 is a large-scale clinically proven joint immunotherapy "golden partner", Qilu Pharmaceuticals using the world's original, independent intellectual property rights to develop PSB205, approved by the FDA, is in the United States a number of institutions to carry out clinical research, domestic clinical is in an orderly manner.
In the future, Qilu Pharmaceuticals plans to make significant progress and breakthroughs in precision targeting therapy, immunotherapy, cell therapy and new drug administration systems to further improve treatment technologies in the fields of cancer, liver disease, diabetes and other major diseases, and actively seize the new high ground of international drug research and development.
Qilu quality: concentrate on professional do a good job in the production of pharmaceutical products every process, every detail, are related to thousands of health and unlimited hope.
hardware and software of drug quality, both hands should be caught, both hands should be hard.
introduced and adopted the world's leading production equipment, testing equipment and technology, established a perfect quality assurance system in line with international standards.
match is a wealth of professional knowledge, experience and a high degree of responsibility of quality testing personnel, equipment, equipment, processes, personnel to build Qilu Pharmaceutical's stringent quality system.
"We want to make every Piece of Qilu manufacturing safe, warm and warm," Sun Ying-man, deputy director of the president's office of Qilu Pharmaceutical Group and deputy general manager of Qilu Pharmaceutical Sales Corporation, said in Qilu Practice, which revitalizes the national pharmaceutical industry.
in fact, "Chilu manufacturing" has been widely recognized by domestic and foreign authorities, is one of the first batch of GMP certification enterprises through the New Edition of the State Food and Drug Administration, is the first U.S. FDA, European EDQM, British MHRA sterile certification enterprises, or the European Union, the United States FDA, Australia TGS, Japan PMDA sterile preparation certification enterprises, is the World Health Organization sterile preparation pre-certification enterprises.
National standards refer to the national drug standards for identification, inspection, content determination, impurities and related substances inspection and other standard substances, and Qilu Pharmaceuticals has nearly 30 "Zilu standards" were identified as international / national standards, of which Oshali platinum injection is the only Chinese and American identified as a comparison preparation of the drug.
insist on concentration, to create standardization, to maintain focus, to achieve refinement, casting professional, the pursuit of the ultimate.
Qilu pharmaceutical do not forget the first heart, remember the mission, so that the common people can use, affordable high-quality domestic good medicine, the "drug bottle" really in their own hands!